Mark Christianson Sells 10,000 Shares of NeuroOne Medical Technologies (NASDAQ:NMTC) Stock

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Director Mark Christianson sold 10,000 shares of NeuroOne Medical Technologies stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $3.18, for a total transaction of $31,800.00. Following the completion of the transaction, the director directly owned 20,692 shares of the company’s stock, valued at approximately $65,800.56. This trade represents a 32.58% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

NeuroOne Medical Technologies Price Performance

Shares of NMTC stock remained flat at $3.00 on Thursday. 17,315 shares of the stock were exchanged, compared to its average volume of 40,985. The stock’s 50 day moving average price is $3.88 and its 200-day moving average price is $4.40. The stock has a market capitalization of $26.11 million, a price-to-earnings ratio of -3.53 and a beta of 0.54. NeuroOne Medical Technologies Corporation has a 12 month low of $2.89 and a 12 month high of $6.96.

NeuroOne Medical Technologies (NASDAQ:NMTC) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.02). NeuroOne Medical Technologies had a negative return on equity of 99.43% and a negative net margin of 68.35%.The business had revenue of $1.86 million for the quarter, compared to analyst estimates of $2.58 million. Research analysts forecast that NeuroOne Medical Technologies Corporation will post -0.36 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Zacks Research cut shares of NeuroOne Medical Technologies from a “strong-buy” rating to a “hold” rating in a research report on Friday, March 13th. LADENBURG THALM/SH SH lifted their target price on shares of NeuroOne Medical Technologies from $1.60 to $8.00 and gave the stock a “buy” rating in a report on Wednesday, May 13th. Finally, Weiss Ratings cut shares of NeuroOne Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, May 11th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $11.67.

Institutional Investors Weigh In On NeuroOne Medical Technologies

A number of hedge funds and other institutional investors have recently modified their holdings of the company. XTX Topco Ltd grew its stake in NeuroOne Medical Technologies by 321.1% during the fourth quarter. XTX Topco Ltd now owns 85,454 shares of the company’s stock worth $65,000 after buying an additional 65,163 shares in the last quarter. Squarepoint Ops LLC bought a new stake in shares of NeuroOne Medical Technologies during the 4th quarter worth approximately $36,000. Essex Investment Management Co. LLC bought a new stake in shares of NeuroOne Medical Technologies during the 4th quarter worth approximately $143,000. Renaissance Technologies LLC boosted its position in shares of NeuroOne Medical Technologies by 10.2% during the 4th quarter. Renaissance Technologies LLC now owns 763,028 shares of the company’s stock worth $578,000 after acquiring an additional 70,428 shares in the last quarter. Finally, Legato Capital Management LLC acquired a new stake in shares of NeuroOne Medical Technologies during the 4th quarter worth approximately $34,000. Institutional investors and hedge funds own 16.07% of the company’s stock.

NeuroOne Medical Technologies Company Profile

NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.

The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.